Danish drugmaker Novo Nordisk has announced that its once-weekly basal insulin icodec, used for the treatment of diabetes in adults, has received a recommendation for marketing authorisation in Europe from the European Medicines Agency’s human medicines committee.
To find out more, CLICK HERE.